Nephrology Fellowship Reseach

Faculty areas of interest:

Obstetric Nephrology-Biomarkers in Preeclampsia and AKI in pregnancy

Cardio renal syndromes-Biomarkers in CRS

Optimal management of CHF in CKD

COVID-AKI

Multi center sponsored studies in the last 10 years:

  1. An Observer-blinded randomized study comparing the safety and immunogenicity of HEPLISAV to licensed vaccine (Engerix-B) among adults (18 to 70 years of age) with CKD
  2. An observational study evaluating the long-term safety and immunogenicity of HEPLISAV compared to Engerix-B in adults with CKD who have previously received at least one hepatitis B vaccine series
  3. START-CKD: Strategies using Darbepoetin alfa to avoid transfusions in CKD
  4. BEACON: Bardoxolone Methyl evaluation in patients with CKD and type 2 diabetes: the occurrence of renal events
  5. A phase 2 randomized double-blind placebo-controlled parallel-group multicenter study to evaluate the efficacy and safety of once daily administration of phosphodiesterase 5 inhibitor (PF-00489791) in adults with type 2 diabetes and overt nephropathy
  6. SALACIA: A phase 3b multicenter randomized single-blind parallel group trial of the effects of titrated oral SAMSCA (Tolvaptan) 15,30, 60 mg QD compared to placebo plus fluid restriction on length of hospital stay and symptoms in subjects hospitalized with dilutional hyponatremia
  7. DIRECT: The genetic contribution to drug induced renal injury: the drug induced renal injury consortium
  8. PHOENIX: A phase 2 trial of the safety and efficacy of Bardoxolone Methyl in patients with rare CKDs
  9. ISCHEMIA: International study of comparative health effectiveness with medical and invasive approaches

NIH (through NYU)

  1. A phase 3 randomized double-blind placebo-controlled study of the efficacy and safety of Roxadustat (FG-4592) for the treatment of anemia in CKD patients not on dialysis
  2. DIAMOND: A multicenter double-blind placebo-controlled randomized withdrawal parallel-group study of Patiromer for the management of hyperkalemia in subjects receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) medications for the treatment of heart failure
  3. GS-US-540-5912: A phase 3 randomized double-blind placebo-controlled parallel-group multicenter study evaluating the efficacy and safety of Remdesivir in participants with severely reduced kidney function who are hospitalized for COVID-19
  4. A multicenter randomized double-blind parallel-group placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with FSGS
  5. Epidemiology of AKI in the ICU (ongoing)